Extract to table

This "double-MAE" construct—a bring-down to a Material Adverse Effect-qualified standard—means that the representations need not be perfectly accurate; rather, the inaccuracies, in the aggregate, must rise to the level of a Material Adverse Effect

2(b) provides a standalone condition that "no Material Adverse Effect shall have occurred since the date of this Agreement that is continuing as of the Closing Date

The halt in enrollment creates a gap in the trial timeline that cannot be made up simply by resuming enrollment at a later date; rather, the statistical analysis plan and the trial's powering assumptions must be revisited in light of the interruption

The realistic regulatory timeline for resolution of the clinical hold and resumption of meaningful clinical development can be summarized as follows: (i) Veridian must submit a complete response to the FDA's safety concerns (Protocol v4

Here, because Veridian is a pre-revenue company, the adverse impact must be assessed primarily through the forward-looking "would reasonably be expected to have" prong